← All trials
NCT04818229
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Feb 28, 2022
- First posted
- Mar 26, 2021
- Last posted
- Nov 30, 2021
- Enrollment
- 64
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Suzhou Connect BiopharmaceuticalsLead sponsor
- Suzhou Connect BiopharmaceuticalsStudy director
- Suzhou Connect BiopharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.